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could emphasize. Second is the increasing
life-saving role of these devices as access
to transplants decreases. Third is the fact
that all LVADs are still subject to the same
entry criteria that were used in the 1970s
for patients with acute failure-to-wean-
from-bypass. These hemodynamic entry
criteria should be reassessed in view of the
changing medical therapy and the fact that
these implantable pumps are for patients
with chronic heart failure on transplant
waiting lists who experience worsening of
heart failure made manifest primarily by
end-organ failure and not by acute hemo-
dynamic compromise.
O. H. Frazier, MD
Director, Cardiopulmonary Transplantation
Texas Heart Institute
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Houston, TX 77225-0345
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Cerebral protection with retrograde
cerebral perfusion
To the Editor:
In their article Bonser and colleagues1
claim that the cerebral flow resulting from
retrograde cerebral perfusion (RCP) is in-
sufficient to make a major contribution to
cerebral oxygenation and that the brain re-
mains ischemic. In the discussion of their
impressive work, the authors stated cor-
rectly that current data suggest that RCP
might provide only little brain perfusion in
human subjects compared with antegrade
baseline cerebral flow. Should we abandon
this adjunct to hypothermic circulatory ar-
rest, or should we explore methods to max-
imize the benefits from its application? The
effort to improve the effectiveness of RCP
during hypothermic circulatory arrest
should combine reduction of the metabolic
activity with simultaneous increase of
blood flow to fulfill the residual metabolic
requirements of the brain. In a small series
my colleagues and I2 demonstrated that the
introduction of vasodilators and anesthetics
into the retrograde perfusate tripled RCP
flow without increase in pressure and with
concomitant suppression of electric activ-
ity. In the present study it is not stated
whether brain electric activity was moni-
tored, and the individual RCP flow is not
specified. Simple pharmacologic manipula-
tions might augment RCP to 20% or 30%
of cerebral flow instead of only 10%. The
administration of potent anesthetics or
other neuroprotective agents might miti-
gate the metabolic needs of the brain. Such
maneuvers will render the brain less isch-
emic, allowing safer circulatory arrest.
Amir Elami, MD
Department of Cardiothoracic Surgery
Hadassah University Hospital
PO Box 12000
Jerusalem 91120, Israel
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Reply to the Editor:
We thank Elami for his comments concern-
ing our work on retrograde cerebral perfu-
sion (RCP).1 We acknowledged in our dis-
cussion that RCP could contribute to
metabolic support during hypothermic cir-
culatory arrest and that this contribution
could be increased by the use of vasodila-
tors. It is also possible that the use of an-
esthetics or neuroprotective agents during
RCP might afford neuroprotection. The se-
ries quoted by Elami, however, describes
only anecdotal evidence from 3 patients
undergoing differing pharmacologic inter-
ventions.2 This report described no moni-
toring of cerebral metabolism or perfusion,
therefore making inferences regarding ce-
rebral metabolic activity and blood flow
unreliable. We have previously reported
that RCP can provide some brain perfu-
sion, but we have questioned what fraction
of retrograde flow provides true brain per-
fusion.3,4 It is quite possible that increased
flow achieved by means of vasodilator ad-
ministration bypasses the brain through
venovenous and venoarterial collaterals.4
Any assumption that increasing flow in-
creases true brain perfusion and neuropro-
tection requires rigorous enquiry. We
would agree that the jury remains out on
RCP and that a beneficial clinical effect
remains to be proven. Such therapeutic in-
terventions therefore require assessment as
part of randomized controlled trials if their
efficacy is to be completely investigated.
Robert Bonser, FRCP, FRCS
Deborah Harrington, MRCS
Domenico Pagano, MD, FRCS
Department of Cardiothoracic Surgery
Queen Elizabeth Hospital
Edgbaston
Birmingham B15 2TH, United Kingdom
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Angiogenesis by means of
endothelial cell transplantation
To the Editor:
In their article, “Angiogenesis by Endothe-
lial Cell Transplantation,” Kim and asso-
ciates1 present results of a novel and in-
triguing approach to angiogenic therapy.
Their preliminary report that endothelial
cell transplantation into a myocardial
scar accelerates angiogenesis suggests
a promising alternative to angiogenic
gene or protein therapy. About the same
time that their article was published, we2
presented similar results before the Amer-
ican Heart Association at our annual sci-
entific session (Anaheim, Calif) in No-
vember 2001.
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